In an effort to give surgeons as many options for their patients as possible, lens companies are working on IOLs that incorporate multifocality and toric correction, lenses that provide pseudo-accommodation. Here are a few that generated buzz at the 2014 American Academy of Ophthalmology meeting.
FDA’s Ophthalmic Devices Advisory Committee has recommended approval for AcrySof IQ ReSTOR Multifocal Toric Intraocular Lens (ReSTOR Toric IOL) for patients undergoing cataract eye surgery who are astigmatic and suffer from presbyopia. Approval is anticipated to be announced in 2015. This will be the first multifocal toric IOL in the US.
Abbott’s TECNIS® Symfony Extended Range of Vision intraocular lens (IOL) received CE Mark in Europe for the treatment of cataract patients who may also have a diminished ability to focus on near objects (presbyopia). Standard IOLs can be used in cataract treatment to improve distance vision, but the TECNIS Symfony IOL is a first-of-its kind lens that is intended to provide patients a continuous range of vision including far, intermediate and near distances with reduced incidence of halo and glare comparable to a monofocal lens. This IOL is not approved for use in the United States but is currently being studied in an FDA trial. Reported in FierceMedicalDevices Abbott (NYSE:ABT) is also set to invest $60 million in an intraocular lens (“IOLs”) manufacturing plant in Malaysia.
In October, Bausch + Lomb announced the TRULIGN™ Toric intraocular lens (IOL) is now available in an expanded power range. The expansion now includes 10.0 to 16.5 (in half diopter steps) making the TRULIGN Toric available to cataract patients throughout the most popular power range.The TRULIGN Toric intraocular lens is the first and only toric IOL in the U.S. that corrects for astigmatism and has the additional capacity to deliver improved vision across a natural range of focus.